Phase 1 N=71 Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector
Healthy
Primary: Maximum Measured Concentration of BI 695501 in Plasma (Cmax) — 3.79; 3.48 Micro-gram (µg) per milliliter (mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=87 A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis
Anemia, Kidney Disease, Chronic
Primary: Mean Dose Required to Achieve Target Hemoglobin of 11-12 g/dL — 150.3; 194.7; 98.7; 66.6 micrograms (mcg)
Phase 2 N=64 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Neuroblastoma · Rhabdomyosarcoma · Ewing's Sarcoma
Primary: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 0; 0; 0 Participants
Phase 2 N=178 Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA Guidelines — 101; 66 days — p=0.113
N/A N=60 Comparison of a Novel 22-gauge Core Biopsy Needle
Solid Pancreatic Mass Lesions · Malignant Neoplasm of Pancreas
Primary: Comparison of Diagnostic Adequacy Scores With SST vs. CST for Cytologic Diagnosis Using a 22G Core Needle. — 5; 6; 24; 24 Participants
Phase 2 N=23 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Carcinoid Syndrome
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase — 4; 3; 3; 2 Participants
Phase 3 N=307 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Actinic Keratosis
Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — 31.3; 1.0 percentage of participants — p=<0.001
Phase 2 N=224 An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
Schizophrenia, Acute Episode
Primary: Least Squares Mean (LSM) Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -14.6; -17.2; -10.0 Score on a Scale — p=0.440
Phase 2 N=12 An Open Label Trial of Bupropion and Naltrexone for Binge Drinking
Binge Drinking
Primary: Number of Participants With Treatment-Associated Adverse Events — 5; 2; 2 Participants
Phase 2 N=71 Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects
Diabetes · Metabolic Syndrome x
Primary: Fasting Insulin — 15.4; 19.1; 20.2 μIU/mL
Phase 4 N=68 Efficacy of IV Acetaminophen for Pain Management
Post-operative Pain
Primary: Opioid Rescue - 48 Hours — 54.4803; 48.9253 Milligrams of intravenous morphine equiv — p=.356
Phase 4 N=36 Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Clinical Response to Tocilizumab — -5.33; -0.5 Units on a scale (PANSS)
Phase 3 N=48 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A
Hemophilia A
Primary: Expansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds — 2.4 treated bleed rate per year
Phase 3 N=316 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
Actinic Keratosis
Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — 25.8; 0.0 percentage of participants — p=<0.001
Phase 2 N=63 Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults
Malaria
Primary: Number of Subjects With Plasmodium Falciparum Parasitemia Defined by a Positive Blood Slide, Following Sporozoite Challenge — 4; 6; 12 Participants — p=<0.0001